fashion -WSS

fashion

author：knowledge 2025-09-29 19:59:39 - browse：2

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Gain of function research would be limited under House proposal

WSS

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Investigation reveals sickle cell patients pressured into sterilizations

Readout LOUD podcast: A CRISPR milestone, biotech mixology

NYU radiologists take on the challenge of expensive MRI machines

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Biogen joins immunology wave with $1.15 billion acquisition of HI

Activists slam private health insurers over coverage restrictions

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

State Dept. review finds Biden bears some blame for Afghanistan failures

Biogen joins immunology wave with $1.15 billion acquisition of HI

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Hospitals look to new technology to keep health care workers safe

United colonoscopy coverage change 'may cost lives,' doctors say

Why medical students are struggling with mental health

Wikipedia

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Bird flu surveillance in wastewater gets boost from consortium

Why medical students are struggling with mental health

Ransomware attacks on hospitals: Study outlines patient impact

Astellas still sees hope in its gene therapy after four deaths

Addressing health care workers' trauma can help fight burnout

knowledge

explore

knowledge

leisure time